Home / News / BioBlast®



Explore our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date. Alternatively, review our weekly BioBlast™ updates below.
Scientific Name: natalizumab


EU | EU grants marketing authorisation for Tysabri® SC (natalizumab)

April 7, 2021

Biogen announced the EC has granted marketing authorisation for Tysabri® (natalizumab) in a subcutaneous presentation. Tysabri® SC is approved for the treatment of relapsing-remitting multiple sclerosis.


Novartis provides updates on Sandoz biosimilar candidates

November 24, 2020

Novartis released its annual report ‘Meet Novartis Management 2020‘. In the report, Novartis announced that GP2411 (biosimilar denosumab candidate) has commenced Ph III trials. Novartis has also indicated it  has planned launches for biosimilar adalimumab and natalizumab in 2021-2023 and denosumab in 2024-2026.

New study demonstrates efficacy of natalizumab in MS

September 10, 2020

Neurology Advisor reported a new study indicates that natalizumab may be more effective than fingolimod or BRACETD in reducing relapses in patients with relapsing-remitting multiple sclerosis.


Phase III trials of natalizumab biosimilar commence

November 18, 2019

Polpharma commences dosing in Phase III trials of proposed natalizumab biosimilar.

Details of clinical trials of biosimilar natalizumab candidate published

October 13, 2019

Polpharma publishes details of upcoming phase III clinical trials of biosimilar natalizumab candidate. The study will involve approximately 260 patients with relapsing-remitting multiple sclerosis.

Pfizer and Polpharma licensing deal for natalizumab biosimilar

September 3, 2019

Pfizer and Polpharma announce licensing deal for natalizumab biosimilar.  Under the agreement, Polpharma will develop, manufacture and supply the product, while Sandoz will be responsible for commercialisation and distribution.


BioBlast® extract From September 3, 2019 to April 7, 2021